AustralieFrV1, PascalFrancis, Corpus, bibRecord, 002823

Efficacy and Safety of Peginterferon Alfa-2a (40KD) Plus Ribavirin in Hepatitis C Patients with Advanced Fibrosis and Cirrhosis

Identifieur interne : 002823 ( PascalFrancis/Corpus ); précédent : 002822; suivant : 002824

Efficacy and Safety of Peginterferon Alfa-2a (40KD) Plus Ribavirin in Hepatitis C Patients with Advanced Fibrosis and Cirrhosis

Auteurs : Savino Bruno ; Mitchell L. Shiffman ; Stuart K. Roberts ; Edward J. Gane ; Diethelm Messinger ; Stephanos J. Hadziyannis ; Patrick Marcellin

Source :

Hepatology : (Baltimore, Md.) [ 0270-9139 ] ; 2010.

RBID : Pascal:10-0133480

Descripteurs français

Pascal (Inist)
- Cirrhose, Peginterféron alfa-2a, Toxicité, Ribavirine, Hépatite virale C, Homme, Fibrose, Gastroentérologie, Immunomodulateur, Antiviral, Anticancéreux.

English descriptors

KwdEn :
- Antineoplastic agent, Antiviral, Cirrhosis, Fibrosis, Gastroenterology, Human, Immunomodulator, Peginterferon alfa-2a, Ribavirin, Toxicity, Viral hepatitis C.

Abstract

The objective of this study is to determine the efficacy and safety of peginterferon alfa-2a (40KD)/ribavirin in patients with advanced fibrosis. Data from 341 genotype 1/4 patients (99 with bridging fibrosis/cirrhosis) treated for 48 weeks and 1547 genotype 2/3 patients (380 with bridging fibrosis/cirrhosis) treated for 16 or 24 weeks enrolled in three randomized international studies were analyzed. Sustained virological response (SVR) rates decreased progressively from 60% in genotype 1/4 patients without advanced fibrosis to 51% in those with bridging fibrosis and 33% in those with cirrhosis (trend test P = 0.0028); and from 76% to 61% and 57%, respectively, in genotype 2/3 patients treated for 24 weeks (trend test P < 0.0001). Irrespective of genotype, patients without advanced fibrosis were more likely to have an earlier response to treatment that was associated with higher SVR rates and lower relapse rates during untreated follow-up. Among patients with or without a diagnosis of advanced fibrosis, rates of SVR and relapse were similar for patients with similar responses in the first 12 weeks. Conclusion: Compared with patients with less severe disease, SVR rates are significantly lower in patients with advanced fibrosis. However, irrespective of genotype and degree of fibrosis, the time to become hepatitis C virus (HCV) RNA undetectable was the strongest predictor of SVR.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0270-9139`
A02	`01`			`@0 HPTLD9`
A03		`1`		`@0 Hepatology : (Baltim. Md.)`
A05				`@2 51`
A06				`@2 2`
A08	`01`	`1`	`ENG`	`@1 Efficacy and Safety of Peginterferon Alfa-2a (40KD) Plus Ribavirin in Hepatitis C Patients with Advanced Fibrosis and Cirrhosis`
A11	`01`	`1`		`@1 BRUNO (Savino)`
A11	`02`	`1`		`@1 SHIFFMAN (Mitchell L.)`
A11	`03`	`1`		`@1 ROBERTS (Stuart K.)`
A11	`04`	`1`		`@1 GANE (Edward J.)`
A11	`05`	`1`		`@1 MESSINGER (Diethelm)`
A11	`06`	`1`		`@1 HADZIYANNIS (Stephanos J.)`
A11	`07`	`1`		`@1 MARCELLIN (Patrick)`
A14	`01`			`@1 AO Fatebenefratelli e Oftalmico @2 Milan @3 ITA @Z 1 aut.`
A14	`02`			`@1 Virginia Commonwealth University Medical Center @2 Blacksburg, VA @3 USA @Z 2 aut.`
A14	`03`			`@1 The Alfred Hospital @2 Melbourne @3 AUS @Z 3 aut.`
A14	`04`			`@1 Auckland Clinical Studies @2 Auckland @3 NZL @Z 4 aut.`
A14	`05`			`@1 IST @2 Mannheim @3 DEU @Z 5 aut.`
A14	`06`			`@1 Henry Dunant Hospital @2 Athens @3 GRC @Z 6 aut.`
A14	`07`			`@1 Service d'Hepatologie and Centre de Recherches Biologiques Bichat Beaujon (Inserm CRB3), Hôpital Beaujon @2 Clichy @3 FRA @Z 7 aut.`
A20				`@1 388-397`
A21				`@1 2010`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 19427 @5 354000180995400060`
A44				`@0 0000 @1 © 2010 INIST-CNRS. All rights reserved.`
A45				`@0 23 ref.`
A47	`01`	`1`		`@0 10-0133480`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Hepatology : (Baltimore, Md.)`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 The objective of this study is to determine the efficacy and safety of peginterferon alfa-2a (40KD)/ribavirin in patients with advanced fibrosis. Data from 341 genotype 1/4 patients (99 with bridging fibrosis/cirrhosis) treated for 48 weeks and 1547 genotype 2/3 patients (380 with bridging fibrosis/cirrhosis) treated for 16 or 24 weeks enrolled in three randomized international studies were analyzed. Sustained virological response (SVR) rates decreased progressively from 60% in genotype 1/4 patients without advanced fibrosis to 51% in those with bridging fibrosis and 33% in those with cirrhosis (trend test P = 0.0028); and from 76% to 61% and 57%, respectively, in genotype 2/3 patients treated for 24 weeks (trend test P < 0.0001). Irrespective of genotype, patients without advanced fibrosis were more likely to have an earlier response to treatment that was associated with higher SVR rates and lower relapse rates during untreated follow-up. Among patients with or without a diagnosis of advanced fibrosis, rates of SVR and relapse were similar for patients with similar responses in the first 12 weeks. Conclusion: Compared with patients with less severe disease, SVR rates are significantly lower in patients with advanced fibrosis. However, irrespective of genotype and degree of fibrosis, the time to become hepatitis C virus (HCV) RNA undetectable was the strongest predictor of SVR.
C02	`01`	`X`		`@0 002B13C03`
C02	`02`	`X`		`@0 002B05C02G`
C02	`03`	`X`		`@0 002B02Q`
C03	`01`	`X`	`FRE`	`@0 Cirrhose @5 01`
C03	`01`	`X`	`ENG`	`@0 Cirrhosis @5 01`
C03	`01`	`X`	`SPA`	`@0 Cirrosis @5 01`
C03	`02`	`X`	`FRE`	`@0 Peginterféron alfa-2a @2 FR @5 04`
C03	`02`	`X`	`ENG`	`@0 Peginterferon alfa-2a @2 FR @5 04`
C03	`02`	`X`	`SPA`	`@0 Peginterferón alfa-2a @2 FR @5 04`
C03	`03`	`X`	`FRE`	`@0 Toxicité @5 07`
C03	`03`	`X`	`ENG`	`@0 Toxicity @5 07`
C03	`03`	`X`	`SPA`	`@0 Toxicidad @5 07`
C03	`04`	`X`	`FRE`	`@0 Ribavirine @2 NK @2 FR @5 08`
C03	`04`	`X`	`ENG`	`@0 Ribavirin @2 NK @2 FR @5 08`
C03	`04`	`X`	`SPA`	`@0 Ribavirina @2 NK @2 FR @5 08`
C03	`05`	`X`	`FRE`	`@0 Hépatite virale C @5 09`
C03	`05`	`X`	`ENG`	`@0 Viral hepatitis C @5 09`
C03	`05`	`X`	`SPA`	`@0 Hepatítis virica C @5 09`
C03	`06`	`X`	`FRE`	`@0 Homme @5 13`
C03	`06`	`X`	`ENG`	`@0 Human @5 13`
C03	`06`	`X`	`SPA`	`@0 Hombre @5 13`
C03	`07`	`X`	`FRE`	`@0 Fibrose @5 14`
C03	`07`	`X`	`ENG`	`@0 Fibrosis @5 14`
C03	`07`	`X`	`SPA`	`@0 Fibrosis @5 14`
C03	`08`	`X`	`FRE`	`@0 Gastroentérologie @5 15`
C03	`08`	`X`	`ENG`	`@0 Gastroenterology @5 15`
C03	`08`	`X`	`SPA`	`@0 Gastroenterología @5 15`
C03	`09`	`X`	`FRE`	`@0 Immunomodulateur @5 30`
C03	`09`	`X`	`ENG`	`@0 Immunomodulator @5 30`
C03	`09`	`X`	`SPA`	`@0 Inmunomodulador @5 30`
C03	`10`	`X`	`FRE`	`@0 Antiviral @5 31`
C03	`10`	`X`	`ENG`	`@0 Antiviral @5 31`
C03	`10`	`X`	`SPA`	`@0 Antiviral @5 31`
C03	`11`	`X`	`FRE`	`@0 Anticancéreux @5 32`
C03	`11`	`X`	`ENG`	`@0 Antineoplastic agent @5 32`
C03	`11`	`X`	`SPA`	`@0 Anticanceroso @5 32`
C07	`01`	`X`	`FRE`	`@0 Virose`
C07	`01`	`X`	`ENG`	`@0 Viral disease`
C07	`01`	`X`	`SPA`	`@0 Virosis`
C07	`02`	`X`	`FRE`	`@0 Infection`
C07	`02`	`X`	`ENG`	`@0 Infection`
C07	`02`	`X`	`SPA`	`@0 Infección`
C07	`03`	`X`	`FRE`	`@0 Forme pégylée @5 37`
C07	`03`	`X`	`ENG`	`@0 Pegylated form @5 37`
C07	`03`	`X`	`SPA`	`@0 Forma pegilada @5 37`
C07	`04`	`X`	`FRE`	`@0 Interféron alpha 2a @2 FR @5 38`
C07	`04`	`X`	`ENG`	`@0 Interferon alpha 2a @2 FR @5 38`
C07	`04`	`X`	`SPA`	`@0 Interferon alfa 2a @2 FR @5 38`
C07	`05`	`X`	`FRE`	`@0 Analogue de nucléoside @5 39`
C07	`05`	`X`	`ENG`	`@0 Nucleoside analog @5 39`
C07	`05`	`X`	`SPA`	`@0 Análogo nucleósido @5 39`
C07	`06`	`X`	`FRE`	`@0 Pathologie de l'appareil digestif @5 40`
C07	`06`	`X`	`ENG`	`@0 Digestive diseases @5 40`
C07	`06`	`X`	`SPA`	`@0 Aparato digestivo patología @5 40`
C07	`07`	`X`	`FRE`	`@0 Pathologie du foie @5 41`
C07	`07`	`X`	`ENG`	`@0 Hepatic disease @5 41`
C07	`07`	`X`	`SPA`	`@0 Hígado patología @5 41`
C07	`08`	`X`	`FRE`	`@0 Cytokine @5 43`
C07	`08`	`X`	`ENG`	`@0 Cytokine @5 43`
C07	`08`	`X`	`SPA`	`@0 Citoquina @5 43`
N21				`@1 088`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 10-0133480 INIST
ET :	Efficacy and Safety of Peginterferon Alfa-2a (40KD) Plus Ribavirin in Hepatitis C Patients with Advanced Fibrosis and Cirrhosis
AU :	BRUNO (Savino); SHIFFMAN (Mitchell L.); ROBERTS (Stuart K.); GANE (Edward J.); MESSINGER (Diethelm); HADZIYANNIS (Stephanos J.); MARCELLIN (Patrick)
AF :	AO Fatebenefratelli e Oftalmico/Milan/Italie (1 aut.); Virginia Commonwealth University Medical Center/Blacksburg, VA/Etats-Unis (2 aut.); The Alfred Hospital/Melbourne/Australie (3 aut.); Auckland Clinical Studies/Auckland/Nouvelle-Zélande (4 aut.); IST/Mannheim/Allemagne (5 aut.); Henry Dunant Hospital/Athens/Grèce (6 aut.); Service d'Hepatologie and Centre de Recherches Biologiques Bichat Beaujon (Inserm CRB3), Hôpital Beaujon/Clichy/France (7 aut.)
DT :	Publication en série; Niveau analytique
SO :	Hepatology : (Baltimore, Md.); ISSN 0270-9139; Coden HPTLD9; Etats-Unis; Da. 2010; Vol. 51; No. 2; Pp. 388-397; Bibl. 23 ref.
LA :	Anglais
EA :	The objective of this study is to determine the efficacy and safety of peginterferon alfa-2a (40KD)/ribavirin in patients with advanced fibrosis. Data from 341 genotype 1/4 patients (99 with bridging fibrosis/cirrhosis) treated for 48 weeks and 1547 genotype 2/3 patients (380 with bridging fibrosis/cirrhosis) treated for 16 or 24 weeks enrolled in three randomized international studies were analyzed. Sustained virological response (SVR) rates decreased progressively from 60% in genotype 1/4 patients without advanced fibrosis to 51% in those with bridging fibrosis and 33% in those with cirrhosis (trend test P = 0.0028); and from 76% to 61% and 57%, respectively, in genotype 2/3 patients treated for 24 weeks (trend test P < 0.0001). Irrespective of genotype, patients without advanced fibrosis were more likely to have an earlier response to treatment that was associated with higher SVR rates and lower relapse rates during untreated follow-up. Among patients with or without a diagnosis of advanced fibrosis, rates of SVR and relapse were similar for patients with similar responses in the first 12 weeks. Conclusion: Compared with patients with less severe disease, SVR rates are significantly lower in patients with advanced fibrosis. However, irrespective of genotype and degree of fibrosis, the time to become hepatitis C virus (HCV) RNA undetectable was the strongest predictor of SVR.
CC :	002B13C03; 002B05C02G; 002B02Q
FD :	Cirrhose; Peginterféron alfa-2a; Toxicité; Ribavirine; Hépatite virale C; Homme; Fibrose; Gastroentérologie; Immunomodulateur; Antiviral; Anticancéreux
FG :	Virose; Infection; Forme pégylée; Interféron alpha 2a; Analogue de nucléoside; Pathologie de l'appareil digestif; Pathologie du foie; Cytokine
ED :	Cirrhosis; Peginterferon alfa-2a; Toxicity; Ribavirin; Viral hepatitis C; Human; Fibrosis; Gastroenterology; Immunomodulator; Antiviral; Antineoplastic agent
EG :	Viral disease; Infection; Pegylated form; Interferon alpha 2a; Nucleoside analog; Digestive diseases; Hepatic disease; Cytokine
SD :	Cirrosis; Peginterferón alfa-2a; Toxicidad; Ribavirina; Hepatítis virica C; Hombre; Fibrosis; Gastroenterología; Inmunomodulador; Antiviral; Anticanceroso
LO :	INIST-19427.354000180995400060
ID :	10-0133480

Links to Exploration step

Pascal:10-0133480

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Efficacy and Safety of Peginterferon Alfa-2a (40KD) Plus Ribavirin in Hepatitis C Patients with Advanced Fibrosis and Cirrhosis</title>
<author><name sortKey="Bruno, Savino" sort="Bruno, Savino" uniqKey="Bruno S" first="Savino" last="Bruno">Savino Bruno</name>
<affiliation><inist:fA14 i1="01"><s1>AO Fatebenefratelli e Oftalmico</s1>
<s2>Milan</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Shiffman, Mitchell L" sort="Shiffman, Mitchell L" uniqKey="Shiffman M" first="Mitchell L." last="Shiffman">Mitchell L. Shiffman</name>
<affiliation><inist:fA14 i1="02"><s1>Virginia Commonwealth University Medical Center</s1>
<s2>Blacksburg, VA</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Roberts, Stuart K" sort="Roberts, Stuart K" uniqKey="Roberts S" first="Stuart K." last="Roberts">Stuart K. Roberts</name>
<affiliation><inist:fA14 i1="03"><s1>The Alfred Hospital</s1>
<s2>Melbourne</s2>
<s3>AUS</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gane, Edward J" sort="Gane, Edward J" uniqKey="Gane E" first="Edward J." last="Gane">Edward J. Gane</name>
<affiliation><inist:fA14 i1="04"><s1>Auckland Clinical Studies</s1>
<s2>Auckland</s2>
<s3>NZL</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Messinger, Diethelm" sort="Messinger, Diethelm" uniqKey="Messinger D" first="Diethelm" last="Messinger">Diethelm Messinger</name>
<affiliation><inist:fA14 i1="05"><s1>IST</s1>
<s2>Mannheim</s2>
<s3>DEU</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hadziyannis, Stephanos J" sort="Hadziyannis, Stephanos J" uniqKey="Hadziyannis S" first="Stephanos J." last="Hadziyannis">Stephanos J. Hadziyannis</name>
<affiliation><inist:fA14 i1="06"><s1>Henry Dunant Hospital</s1>
<s2>Athens</s2>
<s3>GRC</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Marcellin, Patrick" sort="Marcellin, Patrick" uniqKey="Marcellin P" first="Patrick" last="Marcellin">Patrick Marcellin</name>
<affiliation><inist:fA14 i1="07"><s1>Service d'Hepatologie and Centre de Recherches Biologiques Bichat Beaujon (Inserm CRB3), Hôpital Beaujon</s1>
<s2>Clichy</s2>
<s3>FRA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">10-0133480</idno>
<date when="2010">2010</date>
<idno type="stanalyst">PASCAL 10-0133480 INIST</idno>
<idno type="RBID">Pascal:10-0133480</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002823</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Efficacy and Safety of Peginterferon Alfa-2a (40KD) Plus Ribavirin in Hepatitis C Patients with Advanced Fibrosis and Cirrhosis</title>
<author><name sortKey="Bruno, Savino" sort="Bruno, Savino" uniqKey="Bruno S" first="Savino" last="Bruno">Savino Bruno</name>
<affiliation><inist:fA14 i1="01"><s1>AO Fatebenefratelli e Oftalmico</s1>
<s2>Milan</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Shiffman, Mitchell L" sort="Shiffman, Mitchell L" uniqKey="Shiffman M" first="Mitchell L." last="Shiffman">Mitchell L. Shiffman</name>
<affiliation><inist:fA14 i1="02"><s1>Virginia Commonwealth University Medical Center</s1>
<s2>Blacksburg, VA</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Roberts, Stuart K" sort="Roberts, Stuart K" uniqKey="Roberts S" first="Stuart K." last="Roberts">Stuart K. Roberts</name>
<affiliation><inist:fA14 i1="03"><s1>The Alfred Hospital</s1>
<s2>Melbourne</s2>
<s3>AUS</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gane, Edward J" sort="Gane, Edward J" uniqKey="Gane E" first="Edward J." last="Gane">Edward J. Gane</name>
<affiliation><inist:fA14 i1="04"><s1>Auckland Clinical Studies</s1>
<s2>Auckland</s2>
<s3>NZL</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Messinger, Diethelm" sort="Messinger, Diethelm" uniqKey="Messinger D" first="Diethelm" last="Messinger">Diethelm Messinger</name>
<affiliation><inist:fA14 i1="05"><s1>IST</s1>
<s2>Mannheim</s2>
<s3>DEU</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hadziyannis, Stephanos J" sort="Hadziyannis, Stephanos J" uniqKey="Hadziyannis S" first="Stephanos J." last="Hadziyannis">Stephanos J. Hadziyannis</name>
<affiliation><inist:fA14 i1="06"><s1>Henry Dunant Hospital</s1>
<s2>Athens</s2>
<s3>GRC</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Marcellin, Patrick" sort="Marcellin, Patrick" uniqKey="Marcellin P" first="Patrick" last="Marcellin">Patrick Marcellin</name>
<affiliation><inist:fA14 i1="07"><s1>Service d'Hepatologie and Centre de Recherches Biologiques Bichat Beaujon (Inserm CRB3), Hôpital Beaujon</s1>
<s2>Clichy</s2>
<s3>FRA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Hepatology : (Baltimore, Md.)</title>
<title level="j" type="abbreviated">Hepatology : (Baltim. Md.)</title>
<idno type="ISSN">0270-9139</idno>
<imprint><date when="2010">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Hepatology : (Baltimore, Md.)</title>
<title level="j" type="abbreviated">Hepatology : (Baltim. Md.)</title>
<idno type="ISSN">0270-9139</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antineoplastic agent</term>
<term>Antiviral</term>
<term>Cirrhosis</term>
<term>Fibrosis</term>
<term>Gastroenterology</term>
<term>Human</term>
<term>Immunomodulator</term>
<term>Peginterferon alfa-2a</term>
<term>Ribavirin</term>
<term>Toxicity</term>
<term>Viral hepatitis C</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Cirrhose</term>
<term>Peginterféron alfa-2a</term>
<term>Toxicité</term>
<term>Ribavirine</term>
<term>Hépatite virale C</term>
<term>Homme</term>
<term>Fibrose</term>
<term>Gastroentérologie</term>
<term>Immunomodulateur</term>
<term>Antiviral</term>
<term>Anticancéreux</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The objective of this study is to determine the efficacy and safety of peginterferon alfa-2a (40KD)/ribavirin in patients with advanced fibrosis. Data from 341 genotype 1/4 patients (99 with bridging fibrosis/cirrhosis) treated for 48 weeks and 1547 genotype 2/3 patients (380 with bridging fibrosis/cirrhosis) treated for 16 or 24 weeks enrolled in three randomized international studies were analyzed. Sustained virological response (SVR) rates decreased progressively from 60% in genotype 1/4 patients without advanced fibrosis to 51% in those with bridging fibrosis and 33% in those with cirrhosis (trend test P = 0.0028); and from 76% to 61% and 57%, respectively, in genotype 2/3 patients treated for 24 weeks (trend test P < 0.0001). Irrespective of genotype, patients without advanced fibrosis were more likely to have an earlier response to treatment that was associated with higher SVR rates and lower relapse rates during untreated follow-up. Among patients with or without a diagnosis of advanced fibrosis, rates of SVR and relapse were similar for patients with similar responses in the first 12 weeks. Conclusion: Compared with patients with less severe disease, SVR rates are significantly lower in patients with advanced fibrosis. However, irrespective of genotype and degree of fibrosis, the time to become hepatitis C virus (HCV) RNA undetectable was the strongest predictor of SVR.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0270-9139</s0>
</fA01>
<fA02 i1="01"><s0>HPTLD9</s0>
</fA02>
<fA03 i2="1"><s0>Hepatology : (Baltim. Md.)</s0>
</fA03>
<fA05><s2>51</s2>
</fA05>
<fA06><s2>2</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Efficacy and Safety of Peginterferon Alfa-2a (40KD) Plus Ribavirin in Hepatitis C Patients with Advanced Fibrosis and Cirrhosis</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>BRUNO (Savino)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>SHIFFMAN (Mitchell L.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>ROBERTS (Stuart K.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>GANE (Edward J.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>MESSINGER (Diethelm)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>HADZIYANNIS (Stephanos J.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>MARCELLIN (Patrick)</s1>
</fA11>
<fA14 i1="01"><s1>AO Fatebenefratelli e Oftalmico</s1>
<s2>Milan</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Virginia Commonwealth University Medical Center</s1>
<s2>Blacksburg, VA</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>The Alfred Hospital</s1>
<s2>Melbourne</s2>
<s3>AUS</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Auckland Clinical Studies</s1>
<s2>Auckland</s2>
<s3>NZL</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>IST</s1>
<s2>Mannheim</s2>
<s3>DEU</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Henry Dunant Hospital</s1>
<s2>Athens</s2>
<s3>GRC</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Service d'Hepatologie and Centre de Recherches Biologiques Bichat Beaujon (Inserm CRB3), Hôpital Beaujon</s1>
<s2>Clichy</s2>
<s3>FRA</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA20><s1>388-397</s1>
</fA20>
<fA21><s1>2010</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>19427</s2>
<s5>354000180995400060</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2010 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>23 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>10-0133480</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Hepatology : (Baltimore, Md.)</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>The objective of this study is to determine the efficacy and safety of peginterferon alfa-2a (40KD)/ribavirin in patients with advanced fibrosis. Data from 341 genotype 1/4 patients (99 with bridging fibrosis/cirrhosis) treated for 48 weeks and 1547 genotype 2/3 patients (380 with bridging fibrosis/cirrhosis) treated for 16 or 24 weeks enrolled in three randomized international studies were analyzed. Sustained virological response (SVR) rates decreased progressively from 60% in genotype 1/4 patients without advanced fibrosis to 51% in those with bridging fibrosis and 33% in those with cirrhosis (trend test P = 0.0028); and from 76% to 61% and 57%, respectively, in genotype 2/3 patients treated for 24 weeks (trend test P < 0.0001). Irrespective of genotype, patients without advanced fibrosis were more likely to have an earlier response to treatment that was associated with higher SVR rates and lower relapse rates during untreated follow-up. Among patients with or without a diagnosis of advanced fibrosis, rates of SVR and relapse were similar for patients with similar responses in the first 12 weeks. Conclusion: Compared with patients with less severe disease, SVR rates are significantly lower in patients with advanced fibrosis. However, irrespective of genotype and degree of fibrosis, the time to become hepatitis C virus (HCV) RNA undetectable was the strongest predictor of SVR.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B13C03</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B05C02G</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>002B02Q</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Cirrhose</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Cirrhosis</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Cirrosis</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Peginterféron alfa-2a</s0>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Peginterferon alfa-2a</s0>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Peginterferón alfa-2a</s0>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Toxicité</s0>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Toxicity</s0>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Toxicidad</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Ribavirine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>08</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Ribavirin</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>08</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Ribavirina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Hépatite virale C</s0>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Viral hepatitis C</s0>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Hepatítis virica C</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Homme</s0>
<s5>13</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Human</s0>
<s5>13</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Hombre</s0>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Fibrose</s0>
<s5>14</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Fibrosis</s0>
<s5>14</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Fibrosis</s0>
<s5>14</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Gastroentérologie</s0>
<s5>15</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Gastroenterology</s0>
<s5>15</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Gastroenterología</s0>
<s5>15</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Immunomodulateur</s0>
<s5>30</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Immunomodulator</s0>
<s5>30</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Inmunomodulador</s0>
<s5>30</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Antiviral</s0>
<s5>31</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Antiviral</s0>
<s5>31</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Antiviral</s0>
<s5>31</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Anticancéreux</s0>
<s5>32</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Antineoplastic agent</s0>
<s5>32</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Anticanceroso</s0>
<s5>32</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Virose</s0>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Viral disease</s0>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Virosis</s0>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Infection</s0>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Infection</s0>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Infección</s0>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Forme pégylée</s0>
<s5>37</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Pegylated form</s0>
<s5>37</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Forma pegilada</s0>
<s5>37</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Interféron alpha 2a</s0>
<s2>FR</s2>
<s5>38</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Interferon alpha 2a</s0>
<s2>FR</s2>
<s5>38</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Interferon alfa 2a</s0>
<s2>FR</s2>
<s5>38</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Analogue de nucléoside</s0>
<s5>39</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Nucleoside analog</s0>
<s5>39</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Análogo nucleósido</s0>
<s5>39</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Pathologie de l'appareil digestif</s0>
<s5>40</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Digestive diseases</s0>
<s5>40</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Aparato digestivo patología</s0>
<s5>40</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Pathologie du foie</s0>
<s5>41</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Hepatic disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Hígado patología</s0>
<s5>41</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Cytokine</s0>
<s5>43</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Cytokine</s0>
<s5>43</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Citoquina</s0>
<s5>43</s5>
</fC07>
<fN21><s1>088</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 10-0133480 INIST</NO>
<ET>Efficacy and Safety of Peginterferon Alfa-2a (40KD) Plus Ribavirin in Hepatitis C Patients with Advanced Fibrosis and Cirrhosis</ET>
<AU>BRUNO (Savino); SHIFFMAN (Mitchell L.); ROBERTS (Stuart K.); GANE (Edward J.); MESSINGER (Diethelm); HADZIYANNIS (Stephanos J.); MARCELLIN (Patrick)</AU>
<AF>AO Fatebenefratelli e Oftalmico/Milan/Italie (1 aut.); Virginia Commonwealth University Medical Center/Blacksburg, VA/Etats-Unis (2 aut.); The Alfred Hospital/Melbourne/Australie (3 aut.); Auckland Clinical Studies/Auckland/Nouvelle-Zélande (4 aut.); IST/Mannheim/Allemagne (5 aut.); Henry Dunant Hospital/Athens/Grèce (6 aut.); Service d'Hepatologie and Centre de Recherches Biologiques Bichat Beaujon (Inserm CRB3), Hôpital Beaujon/Clichy/France (7 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Hepatology : (Baltimore, Md.); ISSN 0270-9139; Coden HPTLD9; Etats-Unis; Da. 2010; Vol. 51; No. 2; Pp. 388-397; Bibl. 23 ref.</SO>
<LA>Anglais</LA>
<EA>The objective of this study is to determine the efficacy and safety of peginterferon alfa-2a (40KD)/ribavirin in patients with advanced fibrosis. Data from 341 genotype 1/4 patients (99 with bridging fibrosis/cirrhosis) treated for 48 weeks and 1547 genotype 2/3 patients (380 with bridging fibrosis/cirrhosis) treated for 16 or 24 weeks enrolled in three randomized international studies were analyzed. Sustained virological response (SVR) rates decreased progressively from 60% in genotype 1/4 patients without advanced fibrosis to 51% in those with bridging fibrosis and 33% in those with cirrhosis (trend test P = 0.0028); and from 76% to 61% and 57%, respectively, in genotype 2/3 patients treated for 24 weeks (trend test P < 0.0001). Irrespective of genotype, patients without advanced fibrosis were more likely to have an earlier response to treatment that was associated with higher SVR rates and lower relapse rates during untreated follow-up. Among patients with or without a diagnosis of advanced fibrosis, rates of SVR and relapse were similar for patients with similar responses in the first 12 weeks. Conclusion: Compared with patients with less severe disease, SVR rates are significantly lower in patients with advanced fibrosis. However, irrespective of genotype and degree of fibrosis, the time to become hepatitis C virus (HCV) RNA undetectable was the strongest predictor of SVR.</EA>
<CC>002B13C03; 002B05C02G; 002B02Q</CC>
<FD>Cirrhose; Peginterféron alfa-2a; Toxicité; Ribavirine; Hépatite virale C; Homme; Fibrose; Gastroentérologie; Immunomodulateur; Antiviral; Anticancéreux</FD>
<FG>Virose; Infection; Forme pégylée; Interféron alpha 2a; Analogue de nucléoside; Pathologie de l'appareil digestif; Pathologie du foie; Cytokine</FG>
<ED>Cirrhosis; Peginterferon alfa-2a; Toxicity; Ribavirin; Viral hepatitis C; Human; Fibrosis; Gastroenterology; Immunomodulator; Antiviral; Antineoplastic agent</ED>
<EG>Viral disease; Infection; Pegylated form; Interferon alpha 2a; Nucleoside analog; Digestive diseases; Hepatic disease; Cytokine</EG>
<SD>Cirrosis; Peginterferón alfa-2a; Toxicidad; Ribavirina; Hepatítis virica C; Hombre; Fibrosis; Gastroenterología; Inmunomodulador; Antiviral; Anticanceroso</SD>
<LO>INIST-19427.354000180995400060</LO>
<ID>10-0133480</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002823 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 002823 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:10-0133480
   |texte=   Efficacy and Safety of Peginterferon Alfa-2a (40KD) Plus Ribavirin in Hepatitis C Patients with Advanced Fibrosis and Cirrhosis
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Efficacy and Safety of Peginterferon Alfa-2a (40KD) Plus Ribavirin in Hepatitis C Patients with Advanced Fibrosis and Cirrhosis

Efficacy and Safety of Peginterferon Alfa-2a (40KD) Plus Ribavirin in Hepatitis C Patients with Advanced Fibrosis and Cirrhosis

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri